Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 1, 2023PLoS ONEOpen Access

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Although DAPT after PCI reduces MACE and stent thrombosis, optimal DAPT duration remains a concern in high bleeding risk patients.

Does short DAPT (1-3 months) reduce bleeding without increasing MACE compared to standard DAPT (6-12 months) in high bleeding risk patients undergoing PCI?

Population

7,242 HBR patients after PCI across five RCTs

Comparison

Short DAPT (1-3 months) vs standard DAPT (6-12 months)

Design

Systematic review and meta-analysis of RCTs

Follow-up

Median 12-months

Authors

KBKevin R. BaineyGMGuillaume Marquis‐GravelBMBlair J. MacDonald

Discussion

Loading...

Member takes

Overview

Supports short DAPT in high bleeding risk PCI to reduce bleeding; confirms MACE safety and may refine guidelines.

Structured PICO

Does short DAPT (1-3 months) reduce bleeding without increasing MACE compared to standard DAPT (6-12 months) in high bleeding risk patients undergoing PCI?

P
Population
7,242 high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) pooled from 5 RCTs
I
Intervention
Short dual antiplatelet therapy (DAPT) for 1-3 months
C
Comparator
Standard dual antiplatelet therapy (DAPT) for 6-12 months
O
Outcome
Major adverse cardiovascular events (MACE)composite

In high bleeding risk patients undergoing PCI, 1-3 months of DAPT significantly reduces clinically-relevant bleeding compared to 6-12 months without increasing ischemic risk.

Cite This Study

Bainey et al. (2023) studied this question.

synapsesocial.com/papers/6a1961625d70402e70d94fdahttps://doi.org/10.1371/journal.pone.0291061
View Full Paper
Ask AI
Bookmark
Share